Bicara Therapeutics Inc. (BCAX)
NasdaqGM: BCAX
· Prix en temps réel · USD
23.77
+0.14 (0.59%)
À la clôture : Aug 14, 2026, 12:51 PM
Description de l’entreprise
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc.
| Pays | United States |
| Date d’introduction | 13 sept. 2024 |
| Industrie | Biotechnology |
| Secteur | Healthcare |
| Employés | 103 |
| CEO | Dr. Claire Mazumdar Clemon M.B.A., Ph.D. |
Coordonnées
Adresse : 116 Huntington Avenue Boston, MA United States | |
| Site web | https://www.bicara.com |
Données boursières
| Symbole boursier | BCAX |
| Marché | NasdaqGM |
| Exercice fiscal | Jan '25 - Dec '25 |
| Devise de présentation | USD |
| Code CIK | 0002023658 |
| Numéro CUSIP | n/a |
| Numéro ISIN | n/a |
| Identifiant employeur | n/a |
| Code SIC | n/a |
Dirigeants clés
| Nom | Position |
|---|---|
| Dr. Claire Mazumdar Clemon M.B.A., Ph.D. | CEO & Director |
| Mr. Ryan Cohlhepp Pharm.D. | President, COO & Director |
| Mr. Ivan Hyep M.B.A. | CFO & Treasurer |
| Ms. Rachel Frank | Vice President of Investor Relations and Corporate Communications |
| Ms. Lara S. Meisner J.D. | Chief Legal Officer, Compliance Officer & Corporate Secretary |
| Ms. Pauline Dufresne | Chief People Officer |
| Ms. Rachel Salazar | SVP of R&D Strategy and Operations |
| Ms. Sathish Hasige Ph.D. | Senior VP and Head of Technical Operations & Supply Chain |
| Ms. Angela Windt | VP & Head of Regulatory Affairs |
| Dr. Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical & Medical Affairs |